Start-Up Quarterly Statistics, Q2 2014
This article was originally published in Start Up
Start-ups raised $893.9 million in Q2 2014, a 25% drop from last quarter’s record-setting $1.18 billion. Metabolic disease was the most prevalent therapeutic category involved in alliances; seven acquisitions were signed, five in the biopharma sector.
You may also be interested in...
The money raised in Series A financings for biopharma, medtech, and diagnostics start-ups is down 8% from the same period last year, but the number of deals is down even more dramatically.
Roche gets an option to acquire program addressing drug-resistant gram-negative infections when it reaches IND-filing status. Spero is working on a novel target found originally in infected tobacco plants.
Nine $1bn+ alliances were penned in October. Topping the list was a potential $22bn deal between Daiichi Sankyo and Merck for the global development and commercialization of Daiichi’s DXd antibody drug conjugate candidates patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan.